Clinical trial
Study Comparing Zevalin Regimen With no Further Treatment in Patients With…
NCT00322218 · Spectrum Pharmaceuticals, Inc, Industry · Terminated
Key facts
| NCT number | NCT00322218 |
|---|---|
| Title | Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma. |
| Official title | Phase III,Open-label,Prospective,Two-armed,Multicenter Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma. |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Collaborators | Bayer Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, Large Cell, Diffuse |
| Intervention type | Drug |
| Interventions | Zevalin |
| Enrollment | 68 |
| Start date | May 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | May 5, 2006 |
| Last update posted | Jan 19, 2022 |
| Countries | Austria, Belgium, Canada, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Singapore and 7 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: